Incyte Corp INCY
Incyte Corp (Nasdaq: INCY) is a hematology drug developer. Its lead program, INCA033989, is in Phase 3 for Essential Thrombocythemia (mutCALR-positive). Its next catalyst on record is INCA033989 (MF): Phase 3 EXCALIBUR-MF2 trial initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: INCA033989 (MF) — Phase 3 EXCALIBUR-MF2 trial initiation (Q4 2026). 16 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INCA033989 | Essential Thrombocythemia (mutCALR-positive) | antibody | Phase 3 |
| INCA033989 | Myelofibrosis (mutCALR-positive) | antibody | Phase 3 |
| Tafasitamab + lenalidomide + R-CHOP | First-line DLBCL | antibody | Phase 3 |
| Latarcibart | von Willebrand disease | antibody | Phase 3 |
| Axatilimab-csfr | Chronic GVHD (initial treatment with corticosteroids) | antibody | Phase 3 |
| INCB123667 | First-line maintenance ovarian cancer | small molecule | Phase 3 |
| INCB161734 | Metastatic PDAC (first-line, KRASG12D mutation) | small molecule | Phase 3 |
| INCA33890 | MSS colorectal cancer (first-line) | bispecific antibody | Phase 3 |
| Ruxolitinib cream | Hidradenitis suppurativa (mild to moderate) | small molecule | Phase 3 |
| Povorcitinib | Hidradenitis suppurativa (moderate to severe) | small molecule | Phase 3 |
| Povorcitinib | Prurigo nodularis (moderate to severe) | small molecule | Phase 3 |
| Axatilimab-csfr | Chronic GVHD (newly diagnosed, combination with ruxolitinib) | antibody | Phase 2 |
Recent results and decisions
- Oct 29, 2026started Phase 3 study for INCA033989 in essential thrombocythemia is underway or planned.
Advancing multiple registrational programs in Hematology, with Phase 3 studies underway or planned for INCA033989 in essential thrombocythemia (ET)
Filing - Oct 29, 2026started Phase 3 study for latarcibart in von Willebrand disease is underway or planned.
Advancing multiple registrational programs in Hematology, with Phase 3 studies underway or planned for INCA033989 in essential thrombocythemia (ET) and myelofibrosis (MF), and latarcibart in von Willebrand disease (VWD)
Filing - Oct 29, 2026positive Phase 1 data for INCB161734 support an expanding GI Oncology development strategy.
Phase 1 data for INCB161734 and INCA033890 support an expanding GI Oncology development strategy, including multiple ongoing and planned registrational studies in 2027
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.